Elicio Therapeutics (ELTX) risk factors, FY2025 10-K

Risks Related to Our Operating History, Financial Position and Capital Requirements

1. 01We will require substantial additional capital to finance our operations, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our research and development programs, commercialization efforts or cease operations29% rewritten
2. 02Our recurring losses from operations have raised substantial doubt regarding our ability to continue as a going concern
3. 03We may be unsuccessful in raising the capital necessary to address our going concern issues, or if we are successful, it may be on terms that are highly dilutive to existing stockholders
4. 04We have a history of operating losses that are expected to continue for the foreseeable future, and we are unable to predict the extent of future losses, or whether we will generate significant revenues or achieve or sustain profitability
5. 05We have never generated revenue from product sales and may never become profitable94% rewritten
6. 06We have a limited operating history and we expect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance
7. 07Accordingly, the results of any quarterly or annual periods should not be relied upon as indications of future operating performance89% rewritten
8. 08We hold a portion of our cash and cash equivalents that we use to meet our working capital and operating expense needs in deposit accounts that could be adversely affected if the financial institutions holding such funds fail
9. 09Changes in interpretation or application of U.S. GAAP may adversely affect our operating results
10. 10Significant political, trade, regulatory developments, and other circumstances beyond our control, including as a result of recently announced tariffs, could have a material adverse effect on our financial condition or results of operationsNew

Risks Related to the Development of our Product Candidates

1. 11Our product candidates are at an early stage of clinical development and may not be successfully developed or commercialized78% rewritten
2. 12Furthermore, we expect to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and data analysis from such trials. Although we expect to enter into agreements governing our CROs’ committed activities, we have limited influence over their actual performance47% rewritten
3. 13Preliminary results from our nonclinical studies and clinical trials that we announce or publish from time to time may change as more patient data becomes available and as the data undergoes audit and verification procedures
4. 14The FDA or comparable foreign regulatory authorities may disagree with our regulatory plans and we may fail to obtain regulatory approval of our product candidates
5. 15We may not be successful in our efforts to use and expand our discovery engine to build a pipeline of product candidates51% rewritten
6. 16Relative to companies that are more established than we are or that have a larger footprint than we do, we have relatively limited experience as a company in completing preclinical studies to enable the filing of INDs, submitting INDs or commencing, enrolling and conducting clinical trialsNew
7. 17We may seek an accelerated approval development pathway for our product candidates. See “ Description of Our Business—Government Regulation and Product Approval—Accelerated Approval ” for a description of the accelerated approval pathway
8. 18If we apply for orphan drug designation from the FDA, there is no guarantee that we will be able to obtain or maintain this designation, receive this designation for any of our other product candidates, or receive or maintain any corresponding benefits, including periods of exclusivity
9. 19We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
10. 20Any future product candidates for which we intend to seek approval as biological products may face competition sooner than anticipated77% rewritten
11. 21it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our product candidatesNew
12. 22If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
13. 23Any product candidate we advance into clinical trials may cause unacceptable adverse events or have other properties that may delay or prevent our regulatory approval or commercialization or limit our commercial potential
14. 24We may form or seek strategic partnerships or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements
15. 25We rely on CMOs to manufacture our nonclinical and clinical pharmaceutical supplies and expect to continue to rely on CMOs to produce commercial supplies of any approved product candidate, and our dependence on CMOs could adversely impact our business50% rewritten
16. 26providers play a significant role in the conduct of these trials and the subsequent collection and analysis of data from such trialsNew
17. 27We rely on other third parties to store and distribute our product candidates for nonclinical studies and clinical trials that we conduct58% rewritten
18. 28We may incur substantial product liability or indemnification claims relating to the clinical testing of our product candidates

Risks Related to Our Business, Industry and Future Commercialization

1. 29If any product candidate that we successfully develop does not achieve broad market acceptance among physicians, patients, health care payors and the medical community, the revenues that we generate from sales will be limited
2. 30If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, health care payors and patients, we may not generate sufficient revenue from these products and may not become or remain profitable
3. 31If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved
4. 32Corporate and academic collaborators may take actions to delay, prevent, or undermine the success of our products29% rewritten
5. 33Data provided by collaborators and others upon which we rely that has not been independently verified could turn out to be false, misleading, or incomplete
6. 34Even if we are able to commercialize any product candidates, such products may become subject to unfavorable pricing regulations, reimbursement practices, or health care reform initiatives, which would harm our business
7. 35If the market opportunities for any of our product candidates are smaller than we believe they are, our potential revenues may be adversely affected, and our business may suffer. In addition, our estimates of the prevalence of our target populations may be inaccurate
8. 36If we or any CMOs and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business40% rewritten
9. 37We also may encounter problems hiring and retaining the experienced scientific, quality control, and manufacturing personnel needed to manage our manufacturing process, which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements
10. 38Our insurance policies are expensive and protect us only from some business risks, which will leave us exposed to significant uninsured liabilities
11. 39Business interruptions could adversely affect future operations, revenues, and financial conditions, and may increase our costs and expenses
12. 40Indemnity provisions in various agreements potentially expose us to substantial liability for intellectual property infringement, data protection, and other losses

Risks Related to Our Intellectual Property

1. 41Our success will depend upon intellectual property and proprietary technologies, and we may be unable to protect our intellectual property
2. 42We may be forced to litigate to enforce or defend our intellectual property rights, and/or the intellectual property rights of our licensors
3. 43We have rights in some intellectual property that have been discovered through United States government funded programs and thus are subject to federal regulations such as “march-in” rights, certain reporting requirements, and a preference for U.S. industry37% rewritten
4. 44If we or our partners are sued for infringing on the intellectual property rights of third parties, it could be costly and time-consuming, and an unfavorable outcome in any such litigation could have a material adverse effect on our business72% rewritten
5. 45We are not currently involved in, nor have we been threatened with an intellectual property litigation suitNew
6. 46Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements32% rewritten
7. 47Changes in patent law in the United States and in non-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our technologies and product candidates22% rewritten
8. 48Changes in either the patent laws or interpretation of the patent laws could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of our issued patents
9. 49Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
10. 50We may not be able to obtain PTE under the Drug Price Competition and Patent Term Restoration Act of 1984 in the United States and equivalent extension in other countries and, as a result, our product candidates, if approved, may not have patent protection for a sufficient periodNew
11. 51competing products following our patent’s normal expiration by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case if we were accorded PTE. If this were to occur, it could have an adverse effect on our ability to generate product revenueNew
12. 52Weakening patent laws and enforcement by courts in the United States and foreign countries may impact our ability to protect our marketsNew
13. 53If we are unable to protect the confidentiality of our trade secrets, our business and competitive position could be harmed96% rewritten
14. 54Third parties may assert that our employees, consultants, or advisors have wrongfully used or disclosed confidential information or misappropriated trade secrets
15. 55Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business
16. 56Intellectual property rights do not necessarily address all potential threats

Risks Related to Regulatory and Compliance Matters

1. 57The FDA regulatory approval process is lengthy, time-consuming, and inherently unpredictable, and we may experience significant delays in the clinical development and regulatory approval, if any, of our product candidates
2. 58Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements64% rewritten
3. 59Additional regulatory burdens and other risks and uncertainties in foreign markets may limit our growth80% rewritten
4. 60Health care and other reform legislation may increase the difficulty and cost for us and any collaborators we may have to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain29% rewritten
5. 61Our employees, principal investigators, consultants, and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading
6. 62Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs70% rewritten
7. 63compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretationNew
8. 64compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwillNew

Risks Related to Employee and Operations Matters, Managing Growth and Information Technology

1. 65Our future success depends on our ability to retain our key executives and to attract, retain, and motivate qualified personnel
2. 66If we are unable to hire additional qualified personnel, our ability to grow our business may be harmed
3. 67We expect to expand our development, regulatory, and future sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations69% rewritten
4. 68commercialize our product candidates, if approved, will depend in part on our ability to effectively manage our future development and expansionNew
5. 69Our business, operations and clinical development timelines and plans are subject to risks arising from epidemic or pandemic diseases
6. 70Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price25% rewritten
7. 71addition, one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our clinical development goals on schedule and on budgetNew
8. 72Inflation could adversely affect our business and results of operations91% rewritten
9. 73We have broad discretion in the use of our financial resources and may not use them effectively
10. 74U.S. federal income tax reform could adversely affect our business and financial condition25% rewritten
11. 75Changes in tax laws may materially adversely affect our business, prospects, financial condition and operating results20% rewritten
12. 76Our ability to use NOL carryforwards and other tax attributes may be limited
13. 77The market price of our common stock is expected to be volatile, and the market price of our common stock may drop
14. 78Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock29% rewritten
15. 79We will continue to incur costs and demands upon management as a result of complying with the laws, rules and regulations affecting public companies
16. 80We may become involved in securities litigation that could divert management’s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages
17. 81Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management
18. 82We do not anticipate that we will pay any cash dividends in the foreseeable future
19. 83Our stockholders may experience future dilution as a result of future equity offerings33% rewritten
20. 84An active trading market for our common stock may not develop and our stockholders may not be able to resell their shares of common stock for a profit, if at all
21. 85Future sales of a substantial number of shares by existing stockholders, or the perception that such sales could occur, could cause our stock price to decline
22. 86Our largest stockholder has significant influence over us, including influence over decisions that require the approval of stockholders, which could limit our stockholders’ ability to influence the outcome of key transactions, including a change of control36% rewritten
23. 87The terms of our note arrangement with GKCC, an entity controlled by a member of our board of directors, places certain restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our businessNew
24. 88Although we do not expect to rely on the “controlled company” exemption, we may soon become a “controlled company” within the meaning of the Nasdaq listing standards, and we would qualify for exemptions from certain corporate governance requirements
25. 89If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline
26. 90We are expected to take advantage of reduced disclosure and governance requirements applicable to smaller reporting companies and emerging growth companies, which could result in our common stock being less attractive to investors